Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines

Doxorubicin (DOX) is a potent chemotherapeutic drug used as the first line in breast cancer treatment; however, cardiotoxicity is the main drawback of the therapy. Preclinical studies evidenced that the association of simvastatin (SIM) with DOX leads to a better prognosis with reduced side effects a...

Descripción completa

Detalles Bibliográficos
Autores principales: Duarte, Jaqueline Aparecida, Gomes, Eliza Rocha, De Barros, André Luis Branco, Leite, Elaine Amaral
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960841/
https://www.ncbi.nlm.nih.gov/pubmed/36839690
http://dx.doi.org/10.3390/pharmaceutics15020369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960841/
https://www.ncbi.nlm.nih.gov/pubmed/36839690
http://dx.doi.org/10.3390/pharmaceutics15020369

Ejemplares similares